Rethinking Chronic Pain Relief: The α9 Receptor Breakthrough
- Dr Mavani
- Dec 1, 2025
- 4 min read
Updated: 3 days ago
Written by Dr Feroz Mavani
MBChB (Hons), MRCGP, PGDipCert (Digital Health Leadership)
GP Partner & Family Medicine Consultant | NHS Clinical Researcher | Principal Investigator
Peterborough, England, UK
Chronic pain walks into general practice every single day. It sits quietly in the corner of the consultation room, or it arrives exhausted and irritable, having already tried physiotherapy, antidepressants, injections, and sometimes opioids. As a GP, I am constantly balancing relief against risk. We all know how this story can go when opioids become the default rather than the exception.
Against that backdrop, the recent work by Hina Andleeb and colleagues in the laboratory of Roger L. Papke, published in Journal of Medicinal Chemistry, is both scientifically elegant and clinically intriguing. It explores a non opioid pathway for pain relief that, if borne out in human studies, could represent a meaningful shift in how we approach chronic and neuropathic pain in primary care.
A Different Biological Lever: The α9 nAChR
The research centres on nicotinic acetylcholine receptors (nAChRs), a family of ligand gated ion channels involved in neural and immune signalling. Within this family, the α9 subtype has emerged as a particularly interesting target.
Unlike many receptors implicated in analgesia, α9 nAChRs are located primarily in peripheral sensory neurons and immune cells. This matters. From a GP perspective, any analgesic mechanism that avoids direct engagement with central reward pathways or widespread cortical effects immediately signals a potentially safer therapeutic profile.
The α9 receptor appears to modulate inflammatory signalling that contributes to chronic pain states. By influencing this interface between the nervous and immune systems, it offers a mechanistic bridge between neuropathic and inflammatory pain. That is highly relevant in general practice, where pain is rarely purely one or the other.
Precision Over Broad Suppression
In the study, the team developed a series of novel substituted carbamoyl, amido, and heteroaryl dialkylpiperazinium salts with high selectivity for α9 containing nAChRs. Selectivity is not just a pharmacological footnote. It is central to safety.
Other subtypes, such as α7 nAChRs, have distinct physiological roles. Off target activation can produce unintended biological effects. The authors demonstrated that their lead compounds retained analgesic efficacy even in models where α7 receptors were absent, reinforcing that the observed effects were mediated specifically through the α9 pathway.
For those of us who prescribe medications daily, receptor selectivity translates into a more predictable adverse effect profile. The fewer unintended pathways a drug activates, the less collateral physiology we disrupt.
Importantly, this work is now moving beyond experimental pharmacology. The US Patent 12,291,501, granted in May 2025, protects a new generation of drug-like, receptor selective small molecules designed to precisely target α9 and related nicotinic acetylcholine receptors. Earlier research in this area often relied on toxin derived tools that were scientifically useful but impractical as medicines. Securing composition-of-matter protection signals something different: a transition toward compounds intentionally designed for therapeutic development.
From a clinical standpoint, this matters more than patents are often given credit for. Protected intellectual property creates an investable pathway for industry to translate laboratory discoveries into regulated treatments. It also establishes a broader development platform, allowing refinement of formulations and clinical applications as evidence evolves. In practical terms, it moves the concept of non opioid, motor sparing analgesia closer to something that could eventually reach patients rather than remaining an academic promise.
Duration Without Impairment
In preclinical models, two lead compounds produced analgesia lasting up to 72 hours. That duration is notable. Many current non opioid options require frequent dosing, which increases pill burden and the potential for side effects or non adherence.
Equally important, the compounds did not impair motor coordination in animal testing. This addresses a common and very practical concern in primary care. Medications that relieve pain but impair alertness, balance, or reaction time compromise independence. They affect driving, employment, and falls risk in older adults.
An agent that can modulate peripheral pain signalling without affecting cognition or motor function would be highly attractive in day to day general practice.
Why This Matters in General Practice
As GPs, we sit at the intersection of biology, behaviour, and social context. We see the long arc of chronic pain. We also see the downstream consequences of long term opioid use: dependence, tolerance, constipation, hormonal effects, and sometimes devastating harm.
The α9 nAChR pathway represents a mechanistically distinct approach. It does not aim to blunt pain perception through central sedation or reward system engagement. Instead, it appears to recalibrate peripheral sensory and immune signalling. Conceptually, this aligns with a more modern understanding of chronic pain as a dysregulated neuro immune state rather than simply ongoing tissue damage.
That said, it is essential to remain proportionate. These findings are preclinical. Animal models do not always translate cleanly into human benefit. Questions remain regarding pharmacokinetics, long term safety, immunological effects, and real world tolerability. The prolonged duration of action is promising, but it will require careful evaluation in early phase trials.
A Measured Optimism
The study by Andleeb et al. adds to a growing body of work suggesting that peripheral nicotinic receptors, particularly α9 containing subtypes, may represent a viable non opioid analgesic target. It is well funded, methodologically rigorous, and biologically coherent.
As a GP, I find this line of research encouraging not because it offers a quick fix, but because it reflects a deeper shift. We are moving away from blunt pharmacological suppression and toward targeted modulation of specific signalling pathways. That is how safer medicines are usually built.
Chronic pain is unlikely to be solved by a single molecule. It will always require multidisciplinary care. But if therapies emerging from this research can provide sustained analgesia without sedation, cognitive impairment, or dependency risk, they would be a welcome addition to the limited toolkit we currently have.
For now, this remains an area to watch closely. In primary care, where the burden of chronic pain is both clinical and human, even the possibility of a safer, longer lasting non opioid option is worth serious attention.
Reference
Andleeb, H., Papke, R.L., Stokes, C., Richter, K., Herz, S.M., Chiang, K., Kanumuri, S.R.R., Sharma, A., Damaj, M.I., Grau, V., Horenstein, N.A. and Thakur, G.A., 2024. Explorations of agonist selectivity for the α9* nAChR with novel substituted carbamoyl/amido/heteroaryl dialkylpiperazinium salts and their therapeutic implications in pain and inflammation. Journal of Medicinal Chemistry, 67(11), pp.8642–8666. doi:10.1021/acs.jmedchem.3c02429